Time courses of plasma concentration of a new glycopeptide, norvancomycin (NVCM) after single intravenous (iv) and intraperitoneal (ip) injection, and the peak plasma concentrations (Cmax's) of this drug at various doses after single iv injection were determined in guinea pigs. There were significant differences in pharmacokinetic parameters between the two routes of administration and the Cmax linearly increased with the dose used increasing. Guinea pigs with normal hearing were then used to investigate ototoxic liability of NVCM after multiple intravenous administrations (54, 108, 216mg/kg, qd for 14 days). Postrotatory vestibular nystagmus (PRN), auditory brainstem response (ABR) and electron microscopy (SEM TEM) results showed that, similarly to vancomycin, there was no functional or morphological evidence of ototoxicity of NVCM at the dose of 54, 108mg/kg. In the high dose
group (216mg/kg), there was a 0-4dB elevation of hearing threshold but no morphological changes. The results suggested that the ototoxicity of NVCM is absent or minimal after multiple iv administrations within this dose range.
Norvancomycin (NVCM), a new glycopeptide antibiotic, which has the same anti-microbial spectrum as vancomycin (VCM) is used extensively in the clinic to treat methicicillin-resistant Staphylococcus aureus (MRSA) infections1). This antibiotic differs from vancomycin only in that -NHCH3 at the peptide amino terminal of vancomycin has been replaced by -NH2. A few animal experiments on the ototoxicity of VCM have been reported but there is lack of data on ototoxocity of NVCM. It was found that there was no evidence of ototoxicity when VCM was administrated alone to gerbils or guinea pigs intraperitoneally (ip) at dose level of 75-150mg/kg qd for 2 weeks. There was, however, a certain threshold elevation after click stimuli in the animals treated with a dose of 300mg/kg VCM ip2,3). Some studies reported that the addition of a small dose of gentamicin (50mg/kg qd, for 16 days) plus VCM (subcutaneous administration) resulted in a greatly augmented ototoxic effect4). NISHIHARA et al.
however, failed to find such an increased effect in guinea pigs after intramuscular administrations. They ascribed this discrepancy to the difference in route of administration adopted in the experiments5).
In clinic, patients usually receive NVCM intravenously.
There is lack of data on pharmacokinetic parameters of Saline solutions of 50mg/ml of VCM and NVCM drugs were prepared. All drug and saline solutions were administrated intravenously into the left or right vena of pinna, at a rate of 0.1ml/minute, qd for 14 days.
General Observations/Examinations for Ototoxicity Each animal was observed daily for changes in physical appearance and behavior (gait and stance). Righting reflex was conducted by the technique described by WALTZ et al.6) before and after administration. Body weights were determined weekly. Feed consumption was visually estimated every day. Acoustic signals for ABR testing were presented through a TDH-39 earphone. Stimuli were 0.1 msecond click and 4 msecond tone burst (0.1 msecond rise-fall time) delivered at a rate of 11.1/second. Responses were band pass filtered between 100-3000Hz and averaged 128 times. The stimulus intensity was attenuated in 5dB steps starting with 90dB and down to 0dB nHL. The intensity at which a clear brainstem evoked response (wave III) could be still recognized was considered the threshold level.
Morphological Examination Surface Preparation for Hair Cell Counting
After the last auditory test (28 days after starting administration), 5 animals of each group were sacrificed for inner and outer hair cell counting. The technique for this method was described previously elsewhere7).
Scanning and Transmission Electron Microscopy
Five animals of each group were sacrificed for SEM examination and 5 animals for TEM respectively after the last auditory test (28 days after starting administration). The methods have been described previously elsewhere8). Time courses of NVCM concentration in plasma after single administration (iv and ip, 10mg/kg) are shown in Fig, 1 . After iv injection, the plasma drug level reached the peak (Cmax) immediately; the Cmax appeared in plasma about 0.23 hours after ip injection. The Cmax after ip was 18.41% of that after iv administration. The area under the drug concentration-time curves (AUC) after ip was 55.41% of that after iv injection.
General Observations
During the injection period, 4 guinea pigs of NVCM 216mg/kg, 5 animals of VCM 216mg/kg groups died.
Deaths were related to respiratory failure due to neuromuscular blockage. The rest of animals showed a normal walking behavior. They gained body weight and had positive righting reflex after administrations.
Postrotatory Nystagmus (PRN)
The duration of postrotatory nystagmus of each animal before administration arranged from 5 to 9 seconds. As in the saline group, there is no obvious change in average duration of PRN after multiple administrations with NVCM or VCM 54, 108mg/kg. In the groups treated with 216mg/kg, the average duration of PRN decreased slightly during and after the administration, however, there was no significant difference before (0 day) and after (14 days, 28 days) the treatment (Fig. 3) .
Auditory Brainstem Response (ABR)
Input-output functions for ABR are presented in Fig. 4 .
In saline group, with stimulus intensity of click increasing, the output amplitude of wave III increased. In NVCM or VCM treated groups, the observed outputs were very close to or overlapping the outputs of the saline animals after multiple administrations.
Threshold shift (hearing loss) was defined as the difference in thresholds of ABR measured before and after administration. As shown in Table 1 , the threshold shifts of saline group as well as of the groups treated with NVCM or VCM 56, 108mg/kg were around 1dB after administrations. There was no significant difference in hearing loss between the saline and the NVCM or VCM treated groups. In groups injected with NVCM or VCM 216mg/kg, most animals displayed 0-4dB hearing loss after administrations. Two weeks later, the hearing loss was still in this range. The threshold shift was more pronounced 
Transmission Electron Microscopy
In all the NVCM and VCM treated groups (56, 108 and 216mg/kg), the hair cells examined displayed a normal intracellular structure. The cuticular plate was intact with stereocilia extruding outwards. Ample cell organelles such as mitochondria, Golgi bodies and ribosomes appeared in the cytoplasm, which had a normal structure. No swelling afferent or efferent synapses was found under the base of hair cells (Fig. 5) .
Discussion
In the present study, there was significant difference in the time courses of plasma NVCM concentration between single iv and ip administration. After single intravenous injection, the Cmax, which appeared immediately after administration, was approximately 6 times the Cmax after single ip injection. Although Tmax (time at which the peak concentration was reached) was about 0.23 hours after ip injection, indicating that NVCM was absorbed rather rapidly, the AUC from ip injection was much smaller than that from iv injection. The latter was about 2 times the former. These differences in Cmax and AUC between the two administrations indicated that the absorption process of NVCM from injection site to systemic circulation after ip injection was different from that after iv injection. Lower Cmax and smaller AUC after ip administration reflected reduced bioavailability. Although there is no general agreement on the effect of pharmacokinetic parameters of drug on toxicity, many investigations reported that Cmax and AUC of VCM and its analogues were two important parameters affecting toxicity, especially ototoxicity9-11). Significant differences in Cmax and AUC between iv and ip injection found in the present study suggest that ototoxicity induced by NVCM may be different at the same dose used between iv and ip administration. On the other hand, since the real fraction of absorbed NVCM from injection site into blood is not known afteeeee ip injection, it is not possible to evaluate the dose-dependent ototoxicity of NVCM. Relative low Cmax and small AUC after intraperitoneal injection with high dose might produce a false-negative result of ototoxicity.
Thus, in order to obtain reliable data on ototoxicity of NVCM, the intravenous administration route, which is the same route used in clinic, has been adopted in the present animal study.
Low (54mg/kg), middle (108mg/kg) and high (216mg/kg) doses of NVCM were used in the present study. In order to explore any potential ototoxicity of this drug and compare ototoxicity with exposure level, it is essential to ascertain the plasma concentrations of the drug at the various doses used. Peak plasma concentration of NVCM (Cmax) of each guinea pig from various dose groups was measured with HPLC after single iv administration. The results showed that the Cmax increased almost linearly with injection doses increasing (r=0.9941).
This means that the resultant Cmax correlated to the iv injection dose completely. This is because that the guinea pigs had a relatively fixed and limited blood content, and 100% of iv injected NVCM entered and was added into the blood content immediately after injection. That the Cmax's were dose dependent even at high dose levels makes it possible to evaluate the dose-dependent ototoxicity of NVCM in the present study. All the animals treated with NVCM in this study displayed normal walking behavior and normal righting reflex, demonstrating that the equilibrium function of these guinea pigs were perfect after administrations12). PRN is usually used to evaluate vestibular organ sensitivity13).
Inhibition of PRN was often observed in the impairment of vestibular organs induced by aminoglycosides, lead exposure or alcohol administration14,15) In the present study, the average duration of PRN did not change significantly after administration in all NVCM or VCM treated groups. Thus, it is concluded that there was no evidence of vestibulotoxicity of NVCM in these dosages in this study. As in many reported animal studies on ototoxicity of VCM2,4,5), high dosage of NVCM (216mg/kg, qd for 14 days) was used in this study. The purpose was to find potential dose-response ototoxicity of NVCM after systemic application. Considering safety in the clinic, high dose of this drug should be used in animal toxic experiment because there might be difference in ototoxic sensitivity to NVCM between guinea pig and human. Since there was no any evidence of ototoxicity at 54 and 108mg/kg level, high level (216mg/kg) has been adopted to evaluate the ototoxic dose of NVCM. The results showed that only at this dose level did minimal hearing damage appear. The very high ototoxic dose level in animals (216mg/kg, much higher than the normal therapeutic dose) suggested that there is little ototoxicity of NVCM in the clinic. close monitoring are strictly maintained.
